Condition: Connective Tissue Diseases · Sponsor: GlaxoSmithKline
This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD) and interstitial lung disease associated with other connective tissue diseases (CTD-ILD), respectively. The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Philadelphia, Pennsylvania, United States | Recruiting |
| GSK Investigational Site | Ciudad Autonoma Buenos Aires, Argentina | Recruiting |
| GSK Investigational Site | Ciudad Autonoma de Buenos Aire, Argentina | Recruiting |
| GSK Investigational Site | Beijing, China | Recruiting |
| GSK Investigational Site | Zhuzhou, China | Recruiting |
| GSK Investigational Site | Larissa, Greece | Recruiting |
| GSK Investigational Site | Hokkaido, Japan | Recruiting |
| GSK Investigational Site | Tokyo, Japan | Recruiting |
| GSK Investigational Site | Yongsan-Ku Seoul, South Korea | Recruiting |
| GSK Investigational Site | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06716606